Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study.

Olorofim achieved clinical success in over 73% of patients with disseminated coccidioidomycosis, including those with severe CNS involvement, in a phase 2b trial.

• Why it matters: Disseminated coccidioidomycosis often lacks effective treatment options, especially for patients with complex CNS disease, highlighting the need for new therapies.
• What they did: A single-group, open-label study enrolled 41 patients, primarily with CNS disease, who received olorofim alone or with standard care, assessing clinical response at days 42 and 84.
• The result: The study demonstrated high clinical success rates with manageable adverse events, supporting olorofim as a promising treatment for patients with limited options, though randomized trials are needed.